 |
 Video: What is a Stock Split?
|
|
|
| Relmada Therapeutics is a clinical-stage biotechnology company focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity that addresses areas of medical need in the treatment of central nervous system diseases and other disorders. Co.'s primary product candidate, esmethadone, is being developed as an acting, oral agent for the treatment of depression and other potential indications. According to our Relmada Therapeutics stock split history records, Relmada Therapeutics has had 0 splits. | |
|
Relmada Therapeutics (RLMD) has 0 splits in our Relmada Therapeutics stock split history database.
Looking at the Relmada Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Relmada Therapeutics shares, starting with a $10,000 purchase of RLMD, presented on a split-history-adjusted basis factoring in the complete Relmada Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
12/02/2015 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$2.75 |
|
| End price/share: |
$3.83 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
39.27% |
|
| Average Annual Total Return: |
4.02% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$13,926.07 |
|
| Years: |
8.40 |
|
|
|
|
|
